P12 Primary biliary cholangitis (PBC): clinical, serological, histological and evolutionary profile

IntroductionPrimary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease, its diagnosis is based on the presence of two of the following criteria: 1) chronic cholestasis, 2) positive autoimmune work-up, 3) histological criteria of PBCThe aim of our work is to clarify the clinical, serological and evolutionary profile of PBC.Materials and MethodsThis is a retrospective, descriptive study over a period of 19 years from 2003 to 2022 carried out in a hepato-gastroenterology department, involving patients with PBC.The statistical study was carried out using SPSS software.ResultsWe counted over 19 years 117 patients with PBC, the mean age of our patients was 50 years with a standard deviation of 13 years. 91.5% (n=107) were women and 8.5% (n=10) were men. On the clinical side: Icterus pruritus Asthenia portal hypertension 51,3% (n=60) 43,6%(n=60) 32,5% (38) 41%(n=48) Biologically, PBC was seropositive in 62.4% and in addition to cholestasis 54.4% of our patients had associated cytolysis and 30% had IHC.Histologically, 73% of our patients had undergone PBF, with Scheuer stage 2 in 42.5%, Scheuer stage 3 in 30.1% and Scheuer stage 1 in 19.3% of cases. Fibrosis was F3 in 38%, F2 in 32.5%, F4 in 13.3%, F1 in 10.8% and F0 in 4.8% of cases.Associated autoimmune diseases were systematically sought in all patients. This association was found in 47% of our patients. Autoimmune thyroiditis is the most frequent association found in 18.5% of cases (n=20), Overlap syndrome (autoimmune hepatitis) in 16.7% of cases (n=18), dry syndrome in 10.8% of cases (n=12), diabetes in 5.4% of cases (n=6), celiac disease in 1.8% of cases (n=2), psoriasis in 1.8% of cases (n=2)The evaluation of the response to Ursodeoxycholic acid treatment by the Paris II score after one year of treatment showed that 57.3% of patients were responders to the treatment and 35% were poor responders.ConclusionPrimary biliary cholangitis (PBC) is a chronic inflammatory disease of the intrahepatic bile ducts. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies and histologically by lesions of non-suppurative destructive cholangitis. If left untreated, it can progress to cirrhosis, portal hypertension and liver failure.